

5                    **TREATMENT OF FEMALE SEXUAL DYSFUNCTION WITH**  
**VASOACTIVE AGENTS, PARTICULARLY VASOACTIVE INTESTINAL**  
**POLYPEPTIDE AND AGONISTS THEREOF**

10                    **ABSTRACT OF THE DISCLOSURE**

                  Methods for treating female sexual dysfunction are provided. A pharmaceutical  
composition containing a vasoactive agent selected from vasoactive intestinal polypeptide  
(VIP) and VIP agonists is administered to the vagina and/or vulvar region of the  
individual undergoing treatment. The formulations are also useful for improving vaginal  
15                    muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess  
collagen deposition. Pharmaceutical formulations and kits are also provided.